Durvalumab (MEDI4736) in combination with consolidative radiochemotherapy and ablative stereotactic radiotherapy in extensive stage SCLC

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517937-41-00

Acronym

DuCoRa-SCLC

Enrollment

Registered

2024-10-29

Start date

Unknown

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

extensive stage small cell lung cancer (SCLC)

Brief summary

One-year progression-free survival (PFS) rate using investigator assessments according to RECIST 1.1

Interventions

DRUGIMFINZI 50 mg/mL concentrate for solution for infusion.

DRUGCarbomedac 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung

DRUGEto-GRY® 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung

DRUGCisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
One-year progression-free survival (PFS) rate using investigator assessments according to RECIST 1.1	—

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026